[Living-donor lobar lung transplantation for infectious lung diseases].
The rate of infection among lung transplant recipients is several times higher than that among recipients of other organs and is most likely related to the exposure of the allograft to the external environment. Meticulous peri-operative management is mandatory in performing living-donor lobar lung transplantation for patients with infectious lung diseases. All 5 patients with end-stage infectious lung diseases are currently alive for 17-104 months after receiving living-donor lobar lung transplantation at Okayama University Hospital.
Date
Hiroshi
H
Department of Cancer and Thoracic Surgery, Okayama University Graduate School of Medicine, Okayama, Japan.
Yamane
M
M
Toyooka
S
S
Okazaki
M
M
Oto
T
T
Sano
Y
Y
Goto
K
K
D000328:Adult; D001379:Azathioprine / Q000008:administration & dosage; D002315:Cardiopulmonary Bypass; D016572:Cyclosporine / Q000008:administration & dosage; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D019520:Living Donors; D016040:Lung Transplantation; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*; D011239:Prednisolone / Q000008:administration & dosage; D012141:Respiratory Tract Infections / Q000601:surgery*
D016572:Cyclosporine; D011239:Prednisolone; D001379:Azathioprine; D008775:Methylprednisolone